AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36202911 — intervention group
Group type: COMPARATOR
Intervention: Fixed rewards
Number of subjects: 153
Study 36202911 — intervention group
Group type: COMPARATOR
Intervention: No rewards
Number of subjects: 153
Study 33691504 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT)
Number of subjects: 315
Study 33691504 — intervention group
Group type: COMPARATOR
Intervention: Best medical management (control)
Number of subjects: 315
Study 33001232 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day of pioglitazone for 16 weeks
Number of subjects: 41
Study 33001232 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 16 weeks
Number of subjects: 41
Study 33247012 — intervention group
Group type: EXPERIMENTAL
Intervention: 99DOTS-based treatment supervision
Number of subjects: 1890
Study 33247012 — intervention group
Group type: COMPARATOR
Intervention: Routine care (DOT)
Number of subjects: 1890
Study 34375990 — intervention group
Group type: EXPERIMENTAL
Intervention: Loaded Inter-set Stretching (ISS) for 30 seconds at 15% of working load
Number of subjects: 26
Study 34375990 — intervention group
Group type: COMPARATOR
Intervention: Traditional Resistance Training (TR)
Number of subjects: 26
Study 34107933 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehabilitation procedures
Number of subjects: 80
Study 34107933 — intervention group
Group type: COMPARATOR
Intervention: Control group (no oral rehabilitation during the study period)
Number of subjects: 80
Study 35088531 — intervention group
Group type: EXPERIMENTAL
Intervention: Bandage fixation method
Number of subjects: 60
Study 35088531 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube holder fixation
Number of subjects: 60
Study 34277476 — intervention group
Group type: EXPERIMENTAL
Intervention: M+P (Miltefosine 50 mg BID and Pentoxifylline 400 mg TID)
Number of subjects: 43
Study 34277476 — intervention group
Group type: COMPARATOR
Intervention: A+P (Antimonials 20 mg Sb+V/kg/day IV and Pentoxifylline 400 mg TID)
Number of subjects: 43
Study 34277476 — intervention group
Group type: EXPERIMENTAL
Intervention: CL patients
Number of subjects: 43
Study 34277476 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment comparison (M+P vs A+P)
Number of subjects: 43
Study 36112655 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 mg/kg Se methionine
Number of subjects: 300
Study 36112655 — intervention group
Group type: COMPARATOR
Intervention: 0.6, 0.3, and 0.0 mg/kg Se methionine
Number of subjects: 300
Study 33631890 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning method for pancreatic segmentation on CT in arterial phase
Number of subjects: 218
Study 33631890 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning method for pancreatic segmentation on CT in venous phase
Number of subjects: 218
Study 33631890 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups with fat gaps in venous phase
Number of subjects: 218
Study 33631890 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups without fat gaps in venous phase
Number of subjects: 218
Study 32695229 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol 100 mg capsule daily for 3 months
Number of subjects: 60
Study 32695229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 33471452 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower oxygenation target (Pao2 of 60 mm Hg)
Number of subjects: 2928
Study 33471452 — intervention group
Group type: COMPARATOR
Intervention: Higher oxygenation target (Pao2 of 90 mm Hg)
Number of subjects: 2928
Study 32100493 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at the affected side's Tunyan, Fayin and Zhifanliu (Extra)
Number of subjects: 66
Study 32100493 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at both sides' Tunyan, Fayin and Zhifanliu
Number of subjects: 66
Study 32645251 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Sandalore® solution
Number of subjects: 60
Study 32645251 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identically smelling, but non-OR2AT4 activating sandalwood oil)
Number of subjects: 60
Study 32645251 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-assessment
Number of subjects: 60
Study 32388511 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsynchronized nasal intermittent positive pressure ventilation (NS‐NIPPV)
Number of subjects: 220
Study 32388511 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 220
Study 35401778 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (UL)
Number of subjects: 104
Study 35401778 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 104
Study 33243284 — intervention group
Group type: EXPERIMENTAL
Intervention: M. communis preparation in addition to conventional therapy
Number of subjects: 0
Study 33243284 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study 36303227 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal cardiopulmonary resuscitation (ECPR)
Number of subjects: 256
Study 36303227 — intervention group
Group type: COMPARATOR
Intervention: Conventional advanced cardiac life support (ACLS)
Number of subjects: 256
Study 36303227 — intervention group
Group type: COMPARATOR
Intervention: Prehospital return of spontaneous circulation (ROSC)
Number of subjects: 256
Study 32649736 — intervention group
Group type: EXPERIMENTAL
Intervention: GLS4 (120 mg) and ritonavir (100 mg)
Number of subjects: 24
Study 32649736 — intervention group
Group type: EXPERIMENTAL
Intervention: GLS4 (240 mg) and ritonavir (100 mg)
Number of subjects: 24
Study 32649736 — intervention group
Group type: COMPARATOR
Intervention: Entecavir treatment
Number of subjects: 24
Study 34856290 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen-enriched air (FiO2 0.50)
Number of subjects: 7
Study 34856290 — intervention group
Group type: COMPARATOR
Intervention: Ambient air (FiO2 0.21)
Number of subjects: 7
Study 32163927 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrupted sitting (sitting for 3 hours with walking for 3 minutes every 30 minutes)
Number of subjects: 61
Study 32163927 — intervention group
Group type: COMPARATOR
Intervention: Continuous sitting (sitting for 3 hours)
Number of subjects: 61
Study 36122259 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection into coracohumeral ligament (CHL) and inferior glenohumeral capsule (IGHC)
Number of subjects: 120
Study 36122259 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection into posterior glenohumeral recess (PGHR)
Number of subjects: 120
Study 32567391 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient phone calls and virtual wound checks within 72 hours of discharge
Number of subjects: 91
Study 32567391 — intervention group
Group type: COMPARATOR
Intervention: Historical control data
Number of subjects: 91
Study 34429340 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate (240 mg)
Number of subjects: 54
Study 34429340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 32144925 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp acupuncture
Number of subjects: 18
Study 32144925 — intervention group
Group type: COMPARATOR
Intervention: Non-scalp acupuncture
Number of subjects: 18
Study 35340008 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch (TT)
Number of subjects: 0
Study 35340008 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mimic TT)
Number of subjects: 0
Study 35340008 — intervention group
Group type: COMPARATOR
Intervention: Control (regular routine care)
Number of subjects: 0
Study 34321304 — intervention group
Group type: EXPERIMENTAL
Intervention: Dural sealant patch (DSP)
Number of subjects: 40
Study 37480877 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial shunt therapy (Corvia Medical, Inc IASD System II)
Number of subjects: 367
Study 37480877 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline AF burden ≥0.012%
Number of subjects: 367
Study 37480877 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for left atrial reservoir strain
Number of subjects: 367
Study 37480877 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch-detected AF during follow-up
Number of subjects: 367
Study 35049677 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) (36.25 Gy/5 fractions/2 weeks)
Number of subjects: 64
Study 35049677 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionated radiotherapy (CFRT) (76 Gy/38 fractions/7.5 weeks)
Number of subjects: 64
Study 35049677 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 64
Study 35049677 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionated radiotherapy (CFRT)
Number of subjects: 64
Study 32777060 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart team recommendations
Number of subjects: 237
Study 616168499 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam (0.3 mg/kg bolus followed by continuous infusion at 65 micro g/kg/h)
Number of subjects: 60
Study 616168499 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.3 mg/kg bolus followed by continuous infusion at 180 micro g/kg/h)
Number of subjects: 60
Study 616168499 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (bolus and infusion equal to ketamine group)
Number of subjects: 60
Study 36126454 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (30 mg or 40 mg) without PPI (period A)
Number of subjects: 18
Study 36126454 — intervention group
Group type: COMPARATOR
Intervention: Afatinib (30 mg or 40 mg) with 40 mg esomeprazole (period B)
Number of subjects: 18
Study 36126454 — intervention group
Group type: COMPARATOR
Intervention: Afatinib (30 mg or 40 mg) three hours after esomeprazole intake (period C)
Number of subjects: 18
Study 33315169 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term dual antiplatelet therapy (DAPT) (at most 6 months)
Number of subjects: 7142
Study 33315169 — intervention group
Group type: COMPARATOR
Intervention: Long-term dual antiplatelet therapy (DAPT) (at least 12 months)
Number of subjects: 7142
Study 33447025 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol 100/25 μg once daily
Number of subjects: 430
Study 33447025 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermountain Risk Score (IMRS) tertiles
Number of subjects: 430
Study 33447025 — intervention group
Group type: EXPERIMENTAL
Intervention: Summit Lab Score tertiles
Number of subjects: 430
Study 32738409 — intervention group
Group type: EXPERIMENTAL
Intervention: aDBS
Number of subjects: 13
Study 32738409 — intervention group
Group type: EXPERIMENTAL
Intervention: cDBS
Number of subjects: 13
Study 32738409 — intervention group
Group type: COMPARATOR
Intervention: NoStim
Number of subjects: 13
Study 34662548 — intervention group
Group type: EXPERIMENTAL
Intervention: Sbv + topical BC bio-curatives
Number of subjects: 20
Study 34662548 — intervention group
Group type: COMPARATOR
Intervention: Sbv alone
Number of subjects: 20
Study 33781794 — intervention group
Group type: EXPERIMENTAL
Intervention: Health technology education program plus focus groups and routine shared care
Number of subjects: 108
Study 33781794 — intervention group
Group type: COMPARATOR
Intervention: Routine shared care
Number of subjects: 108
Study 35833676 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma Center Trauma-Sensitive Yoga (TCTSY), 10 weekly sessions
Number of subjects: 41
Study 35833676 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Processing Therapy (CPT), 12 weekly sessions
Number of subjects: 41
Study 33826757 — intervention group
Group type: EXPERIMENTAL
Intervention: Incense smoke exposure (exposed group, n = 45)
Number of subjects: 125
Study 33826757 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 80)
Number of subjects: 125
Study 33826757 — intervention group
Group type: EXPERIMENTAL
Intervention: Incense smoke exposure
Number of subjects: 125
Study 34221251 — intervention group
Group type: EXPERIMENTAL
Intervention: 3MDR therapy
Number of subjects: 37
Study 32474728 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 110 mg
Number of subjects: 28
Study 32474728 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg
Number of subjects: 28
Study 32474728 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (both doses)
Number of subjects: 28
Study 35206394 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored online parenting programme ('Parenting Resilient Kids'; PaRK)
Number of subjects: 177
Study 34678740 — intervention group
Group type: EXPERIMENTAL
Intervention: Alloy Primer
Number of subjects: 24
Study 34678740 — intervention group
Group type: EXPERIMENTAL
Intervention: Ea‐Z‐y Primer
Number of subjects: 24
Study 34678740 — intervention group
Group type: EXPERIMENTAL
Intervention: CoJet Sand
Number of subjects: 24
Study 34678740 — intervention group
Group type: COMPARATOR
Intervention: Control (air abrasion with 50‐μm alumina particles)
Number of subjects: 24
Study 32941476 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 42
Study 32941476 — intervention group
Group type: COMPARATOR
Intervention: Protease inhibitor (PI)
Number of subjects: 42
Study 35091036 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraosseous regional administration (IORA) of 500 mg vancomycin
Number of subjects: 24
Study 35091036 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) administration of weight-based (15 mg/kg) vancomycin
Number of subjects: 24
Study 34711835 — intervention group
Group type: EXPERIMENTAL
Intervention: REHACOP (integrative cognitive remediation program)
Number of subjects: 94
Study 34711835 — intervention group
Group type: COMPARATOR
Intervention: Active control (occupational activities)
Number of subjects: 94
Study 36032232 — intervention group
Group type: EXPERIMENTAL
Intervention: Taijiquan combined with acupoint pressing (treatment before sleep)
Number of subjects: 126
Study 36032232 — intervention group
Group type: EXPERIMENTAL
Intervention: Taijiquan combined with acupoint pressing (treatment after sleep)
Number of subjects: 126
Study 36032232 — intervention group
Group type: COMPARATOR
Intervention: Regular psychological counseling (control group)
Number of subjects: 126
Study 36032232 — intervention group
Group type: EXPERIMENTAL
Intervention: Taijiquan combined with acupoint pressing (both treatment groups)
Number of subjects: 126
Study 34020450 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesser mealworm-derived protein
Number of subjects: 24
Study 34020450 — intervention group
Group type: COMPARATOR
Intervention: Milk-derived protein
Number of subjects: 24
Study 35139161 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin withdrawal (placebo)
Number of subjects: 60
Study 35139161 — intervention group
Group type: COMPARATOR
Intervention: Continuation of intravenous immunoglobulin treatment (control)
Number of subjects: 60
Study 33772900 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised community physical activity for 9 months
Number of subjects: 28
Study 33772900 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopped exercise at 9 months
Number of subjects: 28
Study 33141327 — intervention group
Group type: EXPERIMENTAL
Intervention: Group handwashing facilities and daily group handwashing and toothbrushing activities
Number of subjects: 20
Study 33141327 — intervention group
Group type: COMPARATOR
Intervention: Control schools (no intervention)
Number of subjects: 20
Study 35191268 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro needle knife therapy
Number of subjects: 300
Study 35191268 — intervention group
Group type: COMPARATOR
Intervention: Traditional acupuncture
Number of subjects: 300
Study 35191268 — intervention group
Group type: COMPARATOR
Intervention: Oral drug (Merislon, 6 mg, 3 times a day for 2 weeks)
Number of subjects: 300
Study 34252916 — intervention group
Group type: EXPERIMENTAL
Intervention: MaxiPost (BKCa channel opener)
Number of subjects: 26
Study 34252916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 35123457 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose inhaled corticosteroids (ICS) as control
Number of subjects: 120
Study 35123457 — intervention group
Group type: EXPERIMENTAL
Intervention: Taper and subsequently stop ICS
Number of subjects: 120
Study 35332685 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy (MT) additional over inspiratory muscle training (IMT) at 40% of maximal inspiratory pressure (MIP) for 12 weeks (n = 30)
Number of subjects: 60
Study 35332685 — intervention group
Group type: COMPARATOR
Intervention: Inspiratory muscle training (IMT) alone for 12 weeks (n = 30)
Number of subjects: 60
Study 33663463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 32423730 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP 10 cmH20 on deflated lung
Number of subjects: 22
Study 32423730 — intervention group
Group type: COMPARATOR
Intervention: NO CPAP
Number of subjects: 22
Study 34924346 — intervention group
Group type: EXPERIMENTAL
Intervention: TranS-C
Number of subjects: 118
Study 34924346 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation (PE)
Number of subjects: 118
Study 33010649 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress ball intervention (squeezing a stress ball for 10-15 minutes during eight dialysis sessions)
Number of subjects: 45
Study 33010649 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stress ball intervention)
Number of subjects: 45
Study 33010649 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress ball intervention
Number of subjects: 45
Study 35468019 — intervention group
Group type: EXPERIMENTAL
Intervention: CT Colonography Screening (Intervention)
Number of subjects: 21
Study 35468019 — intervention group
Group type: COMPARATOR
Intervention: Control Arm (Control)
Number of subjects: 21
Study 36223397 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise group
Number of subjects: 44
Study 36223397 — intervention group
Group type: COMPARATOR
Intervention: Land exercise group
Number of subjects: 44
Study 33885738 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic retinopexy (PnR)
Number of subjects: 150
Study 33885738 — intervention group
Group type: COMPARATOR
Intervention: Pars plana vitrectomy (PPV)
Number of subjects: 150
Study 33109137 — intervention group
Group type: EXPERIMENTAL
Intervention: Housewives
Number of subjects: 380
Study 33109137 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived low economic status
Number of subjects: 380
Study 33109137 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of partner support
Number of subjects: 380
Study 33109137 — intervention group
Group type: EXPERIMENTAL
Intervention: Unplanned pregnancy
Number of subjects: 380
Study 33109137 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal illness after delivery
Number of subjects: 380
Study 33109137 — intervention group
Group type: EXPERIMENTAL
Intervention: Residing in Southwest‐Asmara
Number of subjects: 380
Study 36273151 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of an evidence-based decision tool for prioritizing preventive services
Number of subjects: 600
Study 36273151 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 600
Study 34365905 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose GOS (10-15 grams/day)
Number of subjects: 377
Study 34365905 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose GOS (15-20 grams/day)
Number of subjects: 377
Study 34365905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 377
Study 34365905 — intervention group
Group type: EXPERIMENTAL
Intervention: GOS (both doses)
Number of subjects: 377
Study 35597066 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (225 patients), titrated according to clinical response
Number of subjects: 440
Study 35597066 — intervention group
Group type: COMPARATOR
Intervention: Placebo (215 patients)
Number of subjects: 440
Study 35597066 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (225 patients)
Number of subjects: 440
Study 34587382 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1222 (ChAdOx1 nCoV-19) vaccine
Number of subjects: 32451
Study 34587382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32451
Study 35670987 — intervention group
Group type: EXPERIMENTAL
Intervention: Triggered escalating real‐time adherence (TERA) intervention with remote coaching, electronic dose monitoring (EDM), and outreach for missed/delayed doses
Number of subjects: 89
Study 35670987 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 89
Study 35670987 — intervention group
Group type: EXPERIMENTAL
Intervention: TERA
Number of subjects: 89
Study 35670987 — intervention group
Group type: COMPARATOR
Intervention: SOC
Number of subjects: 89
Study 32503806 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified treatment schedules, telemedicine facilitation, decreased data collection requirements
Number of subjects: 0
Study 34568490 — intervention group
Group type: EXPERIMENTAL
Intervention: One-fifth of bodyweight traction
Number of subjects: 45
Study 34568490 — intervention group
Group type: EXPERIMENTAL
Intervention: One-third of bodyweight traction
Number of subjects: 45
Study 34568490 — intervention group
Group type: EXPERIMENTAL
Intervention: One-half of bodyweight traction
Number of subjects: 45
Study 34568490 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study 32381097 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-visiting program
Number of subjects: 39
Study 32381097 — intervention group
Group type: EXPERIMENTAL
Intervention: Center-based parenting groups
Number of subjects: 39
Study 32381097 — intervention group
Group type: COMPARATOR
Intervention: Control areas (not receiving intervention initially)
Number of subjects: 39
Study 35922771 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofol
Number of subjects: 120
Study 35922771 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 120
Study 33720997 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily SMS reminders about insulin injections
Number of subjects: 92
Study 33720997 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 92
Study 32709172 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ultrasound-guided Erector Spinae Plane (ESP) block with 20 mL of bupivacaine 0.375% plus 5 ug/mL adrenaline (1:200000)
Number of subjects: 48